337 related articles for article (PubMed ID: 12952927)
61. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate.
Bowe AE; Finnegan R; Jan de Beur SM; Cho J; Levine MA; Kumar R; Schiavi SC
Biochem Biophys Res Commun; 2001 Jun; 284(4):977-81. PubMed ID: 11409890
[TBL] [Abstract][Full Text] [Related]
62. Parathyroid hormone effects on serum 1,25-dihydroxyvitamin D levels in patients with X-linked hypophosphatemic rickets: evidence for abnormal 25-hydroxyvitamin D-1-hydroxylase activity.
Lyles KW; Drezner MK
J Clin Endocrinol Metab; 1982 Mar; 54(3):638-44. PubMed ID: 6276432
[TBL] [Abstract][Full Text] [Related]
63. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism.
Shimada T; Yamazaki Y; Takahashi M; Hasegawa H; Urakawa I; Oshima T; Ono K; Kakitani M; Tomizuka K; Fujita T; Fukumoto S; Yamashita T
Am J Physiol Renal Physiol; 2005 Nov; 289(5):F1088-95. PubMed ID: 15998839
[TBL] [Abstract][Full Text] [Related]
64. gamma-L-glutamyl-L-DOPA inhibits Na(+)-phosphate cotransport across renal brush border membranes and increases renal excretion of phosphate.
de Toledo FG; Thompson MA; Bolliger C; Tyce GM; Dousa TP
Kidney Int; 1999 May; 55(5):1832-42. PubMed ID: 10231445
[TBL] [Abstract][Full Text] [Related]
65. Marked hypophosphatemia with decreased serum 1,25-dihydroxyvitamin D in a patient with hepatocellular carcinoma complicating liver cirrhosis.
Mizuno Y; Masaki N; Hashimoto H; Ogata I; Aizawa C; Fujiwara K; Toda G; Mori M; Machinami R; Kurokawa K
Jpn J Med; 1991; 30(1):81-6. PubMed ID: 1713978
[TBL] [Abstract][Full Text] [Related]
66. Secreted Frizzled-related proteins can regulate metanephric development.
Yoshino K; Rubin JS; Higinbotham KG; Uren A; Anest V; Plisov SY; Perantoni AO
Mech Dev; 2001 Apr; 102(1-2):45-55. PubMed ID: 11287180
[TBL] [Abstract][Full Text] [Related]
67. Regulation of phosphate homeostasis by the phosphatonins and other novel mediators.
Shaikh A; Berndt T; Kumar R
Pediatr Nephrol; 2008 Aug; 23(8):1203-10. PubMed ID: 18288501
[TBL] [Abstract][Full Text] [Related]
68. Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy.
Ovejero D; El-Maouche D; Brillante BA; Khosravi A; Gafni RI; Collins MT
J Bone Miner Res; 2017 Aug; 32(8):1667-1671. PubMed ID: 28459498
[TBL] [Abstract][Full Text] [Related]
69. Type IIc sodium-dependent phosphate transporter regulates calcium metabolism.
Segawa H; Onitsuka A; Kuwahata M; Hanabusa E; Furutani J; Kaneko I; Tomoe Y; Aranami F; Matsumoto N; Ito M; Matsumoto M; Li M; Amizuka N; Miyamoto K
J Am Soc Nephrol; 2009 Jan; 20(1):104-13. PubMed ID: 19056871
[TBL] [Abstract][Full Text] [Related]
70. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation.
Pande S; Ritter CS; Rothstein M; Wiesen K; Vassiliadis J; Kumar R; Schiavi SC; Slatapolsky E; Brown AJ
Nephron Physiol; 2006; 104(1):p23-32. PubMed ID: 16691036
[TBL] [Abstract][Full Text] [Related]
71. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma.
Leaf DE; Pereira RC; Bazari H; Jüppner H
J Clin Endocrinol Metab; 2013 Mar; 98(3):887-91. PubMed ID: 23393166
[TBL] [Abstract][Full Text] [Related]
72. JAK3 talks down to renal 25-hydroxyvitamin D 1α-hydroxylase.
White JH
Kidney Int; 2015 Apr; 87(4):678-9. PubMed ID: 25826541
[TBL] [Abstract][Full Text] [Related]
73. Phosphatonins: new hormones that control phosphorus homeostasis.
Marcucci G; Masi L; Brandi ML
Expert Rev Endocrinol Metab; 2008 Jul; 3(4):513-526. PubMed ID: 30290433
[TBL] [Abstract][Full Text] [Related]
74. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway.
Yamashita T; Konishi M; Miyake A; Inui K; Itoh N
J Biol Chem; 2002 Aug; 277(31):28265-70. PubMed ID: 12032146
[TBL] [Abstract][Full Text] [Related]
75. Oncogenic osteomalacia secondary to nasal tumor with decreased urinary excretion of cAMP.
Kawai Y; Morimoto S; Sakaguchi K; Yoshino H; Yotsui T; Hirota S; Inohara H; Nakagawa T; Hattori K; Kubo T; Yang J; Fujiwara N; Ogihara T
J Bone Miner Metab; 2001; 19(1):61-4. PubMed ID: 11156476
[No Abstract] [Full Text] [Related]
76. Oncogenic osteomalacia, a rare paraneoplastic syndrome due to phosphate wasting--a case report and review of the literature.
Woznowski M; Quack I; Stegbauer J; Büchner N; Rump LC; Schieren G
Clin Nephrol; 2008 Nov; 70(5):431-8. PubMed ID: 19000546
[TBL] [Abstract][Full Text] [Related]
77. The genetic polymorphisms of XPR1 and SCL34A3 are associated with Fanconi syndrome in Chinese patients of tumor-induced osteomalacia.
Jiang Y; Li X; Feng J; Li M; Wang O; Xing XP; Xia WB
J Endocrinol Invest; 2021 Apr; 44(4):773-780. PubMed ID: 32725396
[TBL] [Abstract][Full Text] [Related]
78. Candidate 56 and 58 kDa protein(s) responsible for mediating the renal defects in oncogenic hypophosphatemic osteomalacia.
Rowe PS; Ong AC; Cockerill FJ; Goulding JN; Hewison M
Bone; 1996 Feb; 18(2):159-69. PubMed ID: 8833210
[TBL] [Abstract][Full Text] [Related]
79. Hepatic phosphate uptake and subsequent nerve-mediated phosphaturia are crucial for phosphate homeostasis following portal vein passage of phosphate in rats.
Yasuda S; Inoue K; Matsui I; Matsumoto A; Katsuma Y; Okushima H; Imai A; Sakaguchi Y; Kaimori JY; Yamamoto R; Mizui M; Isaka Y
Sci Rep; 2023 Apr; 13(1):5794. PubMed ID: 37031318
[TBL] [Abstract][Full Text] [Related]
80. Sodium-phosphate cotransporters, nephrolithiasis and bone demineralization.
Prié D; Beck L; Friedlander G; Silve C
Curr Opin Nephrol Hypertens; 2004 Nov; 13(6):675-81. PubMed ID: 15483460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
